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Vitamin D receptor agonists (VDRAs) directly suppress parathyroid hormone (PTH) mRNA expression. Diﬀerent VDRAs are
known to have diﬀerential eﬀects on serum calcium (Ca), which may also aﬀect serum PTH levels since serum Ca regulates PTH
secretion mediated by the Ca-sensing receptor (CaSR). In this study, we compared the eﬀects of paricalcitol and doxercalciferol on
regulating serum Ca and PTH, and also the expression of PTH, VDR, and CaSR mRNA. The 5/6 nephrectomized (NX) Sprague-
Dawley rats on a normal or hyperphosphatemia-inducing diet were treated with vehicle, paricalcitol, or doxercalciferol for two
weeks. Both drugs at the tested doses (0.042–0.33μg/kg) suppressed PTH mRNA expression and serum PTH eﬀectively in the 5/6
NXrats,butparicalcitolwaslesspotentinraisingserumCathandoxercalciferol.Inpigparathyroidcells,paricalcitolandtheactive
form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and
inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more eﬀectively. The
multiple eﬀects of VDRAs on modulating serum Ca, parathyroid cell proliferation, and the expression of CaSR and PTH mRNA
reﬂect the complex involvement of the vitamin D axis in regulating the mineral homeostasis system.
1.Introduction
The steroid hormone, 1, 25-dihydroxyvitamin D3 (1,
25(OH)2D3, calcitriol), activates multiple signaling
pathways in various cells and tissues. Although the
synthesis of vitamin D3 occurs naturally in the skin with
adequate sunlight exposure, vitamin D3 is not active and
needs to be converted to 25(OH)D3 in the liver. From
the liver, 25(OH)D3 is transported to the kidney and
hydroxylated by 25-hydroxyvitamin D3 1α-hydroxylase to
form the active hormone, 1, 25-dihydroxyvitamin D3 or
calcitriol [1]. Calcitriol is metabolized by 25-hydroxyvitamin
D-24-hydroxylase (CYP24A1) [2] to yield the biliary
excretory product calcitroic acid. The binding of 1, 25-
dihydroxyvitamin D3 or its analogs to the vitamin D
receptor (VDR), a nuclear receptor, activates VDR to recruit
cofactors to form the VDR/cofactor complex, which binds
to vitamin D response elements in the promoter region of
t a r g e tg e n e st or e g u l a t eg e n et r a n s c r i p t i o n[ 3].
During the past three decades, a majority of the studies
in the VDR ﬁeld have focused on elucidating its role in
mineral homeostasis, which covers regulation of parathyroid
hormone, intestinal calcium, and phosphate absorption
and bone metabolism [4]. As a result of those studies,
many new VDR agonists or activators (VDRAs) have been
developed in an eﬀort to curtail the increases in serum
Ca associated with calcitriol. Currently new VDRAs such
as paricalcitol and doxercalciferol are commonly used to
manage hyperparathyroidism secondary to chronic kidney
disease (CKD) [1]. Paricalcitol, like calcitriol, activates
VDR directly, while doxercalciferol is inactive until it is
metabolized in the liver to form 1, 25(OH)2D2 (the major
active metabolite) and 1, 24(OH)2D2(the minor active
metabolite).2 International Journal of Endocrinology
The serum PTH level is maintained by various mech-
anisms. Decreases in serum calcium (Ca) (hypocalcemia)
and prolonged increases in serum phosphate (hyperphos-
phatemia) stimulate the parathyroid gland to secrete PTH
from its storage granules. Ca regulates PTH secretion from
the storage mediated by the Ca-sensing receptor (CaSR),
while VDRAs down-regulate PTH gene expression at the
transcriptional level. However, diﬀerent VDRAs also exert
diﬀerential eﬀects on raising serum Ca, which may aﬀect
serum PTH levels. In an eﬀort to investigate how the vitamin
Da x i sm o d u l a t e sd i ﬀerent factors involved in the mineral
homeostasis system, we compared two VDRAs, paricalcitol
and doxercalciferol, on modulating serum Ca and PTH,
and the expression of VDR, PTH and CaSR mRNA in
5/6 nephrectomized rats and in primary culture of pig
parathyroid cells. We also studied the eﬀect of VDRAs
on parathyroid cell proliferation and employed confocal
microscopy to examine the VDR subcellular distribution
pattern after parathyroid cells were treated with paricalcitol
or active doxercalciferol. Our results suggest that paricalcitol
and doxercalciferol regulate multiple factors involved in the
mineral homeostasis system in a similar manner with some
subtle diﬀerences.
2. Methods
2.1.Materials. 1α-hydroxyvitaminD2 (1α(OH)D2,do x ercal-
ciferol), the major active metabolite of doxercalciferol (1α,
25-dihydroxyvitaminD2,1,25(OH)2D2),and19-nor-1α,25-
dihydroxyvitamin D2 (19-nor-1α, 25-(OH)2D2, paricalcitol)
were from Abbott Laboratories. Other reagents were of
analytical grade.
2.2. Subtotally Nephrectomized Rats. The 5/6 nephrec-
tomized (NX) uremic rats were obtained from Charles
River. The nephrectomy was performed on male, Sprague-
Dawley rats with a standard two-step surgical ablation
procedure. About six weeks after the surgery, the rats were
treated with vehicle (5% ethanol +95% propylene glycol,
0.4mL/kg), paricalcitol or doxercalciferol at the indicated
doses intraperitoneally (i.p.), 3 times/week, for two weeks.
Twenty-four hours after the last dosing, animals were anes-
thetized with ketamine and blood samples were collected.
In the study measuring PTH mRNA in the parathyroid
gland, about two weeks after the surgery the rats were
put on a hyperphosphatemia-inducing diet containing 0.9%
phosphorous and 0.6% calcium for 4 weeks, followed by
treatment with vehicle, paricalcitol or doxercalciferol at the
indicated dose (i.p., 3 times/week) for two weeks. Twenty-
four hours after the last dosing, animals were anesthetized
with ketamine and blood and parathyroid gland were
collected.
2.3. Measurements of Physiological Parameters. Serum total
calcium (Ca), serum phosphorus (Pi), creatinine, and BUN
concentrations were measured using an Abbott Aeroset.
SerumPTHwasmeasuredusingaratintactparathyroidhor-
mone (PTH) ELISA kit obtained from ALPCO (Windham,
NH). Blood iCa was determined using an i-STAT portable
clinical analyzer with an EG7+ cartridge.
2.4. Real-Time RT-PCR. Real-time reverse Transcription-
PCR was performed with a iCycler (BioRad, Hercules, CA).
Each sample has a ﬁnal volume of 25μL containing 100ng of
cDNA, 0.4μM each of the forward and reverse PCR primers
and 0.1μM of the TaqMan probe (Applied Biosystems).
Temperature conditions consisted of a step of 5 minutes at
95
◦C,followedby40cyclesof60
◦Cfor1minuteand95
◦Cfor
15 seconds. Data was collected during each extension phase
of the PCR reaction and analyzed with the software package
(BioRad). Threshold cycles were determined for each gene.
2.5. Pig Parathyroid Cell Cultures. Freshly harvested pig
parathyroid glands were purchased from Analytical Bio-
logical Systems (Wilmington, DE). Dispersed pig parathy-
roid cells were prepared using a method adapted from
those previously described for isolating bovine parathyroid
cells [5, 6]. Brieﬂy, pig parathyroid glands were rinsed in
100% ethanol ﬁrst and then in ice-cold Buﬀer A (20mM
HEPES, pH 7.5, in DMEM without bicarbonate, plus 1mM
Ca, 1mM magnesium, 500units/mL penicillin, 500μg/mL
streptomycin, 1.25μg/mL amphotericin B, and 100μg/mL
gentamycin). The glands were trimmed of extraneous fatty
tissue and ﬁnely minced into fragments. The minced pieces
were washed twice with ice-cold PBS and incubated in Buﬀer
A containing 2mg/mL collagenase Type 1 (Worthington
no. 4196) and 50μg/mL DNAse 1 (Sigma no. DN25,
10mL/gram of tissue) for 1.5–3.0 hours at 37
◦Ci naC O 2
incubator. During incubation the tissue was stirred every
30 minutes. At the end of the digestion period large pieces
were removed and the cell suspension was ﬁltered through
70μm and then 40μm cell strainers (BD, Falcon). The cells
were washed 3X with ice-cold PBS and gently resuspended
in Medium A containing DMEM: Ham’s F-12 (50 : 50),
10% FBS, 1.2mM Ca, 15mM HEPES, 100IU/mL penicillin,
100μg/mLstreptomycin,0.25μg/mLamphotericinB,1 : 100
Insulin-Tranferrin-Selenium (GIBCO). The cells were then
incubated overnight at 37
◦Ci naC O 2 incubator, and washed
for at least 3 times in Medium A. A > 80% viability (as
determinedbytrypanbluestaining)wasobtained.Cellswere
used within 2 days for experiments.
2.6. Proliferation Assay. Pig parathyroid cells were plated at 1
× 107 cells/well into 48-well plates (Corning, Corning, NY).
The cell number was determined at plating (Day 0) and after
cells were treated with test agents for 72 hours.
2.7.ConfocalMicroscopy. Cellsgrowninfour-chamberslides
were treated with test agent for diﬀerent periods of time.
Cells were washed with PBS for 30 seconds, ﬁxed with
4% formaldehyde in PBS for 15 minutes, washed again
with PBS, and then treated with 0.2% Triton X-100 in
PBS for 5 minutes. The slides were rinsed with PBS and
incubated with PBS plus 1% BSA for 1 hour at room
temperature. The slides were then incubated with a mouse
anti-VDR monoclonal antibody (50-fold dilution, SantaInternational Journal of Endocrinology 3
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Figure 1: The structures of doxercalciferol, the active form of doxercalciferol and paricalcitol.
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Figure 2: The serum creatinine and BUN levels in 5/6 nephrectomized (NX) uremic rats. 5/6 NX rats on normal diet were treated with
vehicle, paricalcitol, or doxercalciferol at indicated doses, i.p., 3 times/week, for two weeks (n = 8–12 per group). Sham-vehicle rats were
dosed with vehicle. Handling of animals was as described in Materials and Methods. Blood samples were collected for the measurement of
serumcreatinineandBUN.Mean ±standarderrorwascalculatedforeachgroup.Unpairedt-testwith95%conﬁdenceintervalsofdiﬀerence
was performed for statistical comparisons. ∗P<. 05 versus Day 0 (before dosing at six weeks after the surgery). Day 13: after dosing with
vehicle or drugs.
CruzBiotechnology,SantaCruz,CA)inPBSfor>20hoursat
4◦C. After incubation, slides were rinsed with PBS, blocked
with 1% BSA in PBS for 15 minutes, and then incubated
with a secondary antibody (Alexa Fluor 488 goat antimouse
IgG; Molecular Probes, Eugene, OR) for 1 hour at 37
◦C,
followed by another wash with PBS. To stain nuclei, slides
were treated with ribonuclease-A (Sigma, St. Louis, MO) at
100μg/mL in PBS for 20 minutes at 37
◦C, followed by PBS
wash and then incubated with propidium iodide (10μg/mL,
Molecular Probes) for 15 minutes at room temperature
and washed again with PBS. The slides were mounted
and photographed with a Bio-Rad MRC 1024 confocal
microscope.
3. Results
The structures of doxercalciferol, the major active metabolite
ofdoxercalciferol(1,25(OH)2D2),andparicalcitolareshown
in Figure 1. The eﬀects of paricalcitol and doxercalciferol
o np h y s i o l o g i c a lp a r a m e t e r sw e r eﬁ r s tc o m p a r e di nt h e5 / 6
NX rats on a normal diet. Figure 2 show that the serum
creatinine and BUN levels were signiﬁcantly elevated in
the 5/6 nephrectomized (NX) rats (versus Sham-vehicle),
indicating a uniform disease state. Paricalcitol or doxercal-
ciferol at the tested doses had no dose-dependent eﬀect on
creatinine or BUN (versus 5/6 NX-vehicle). Figures 3(a) and
3(b) shows that both ionized Ca and serum Ca were not4 International Journal of Endocrinology
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Figure 3: The ionized Ca, serum Ca, Pi, and PTH levels in uremic rats. Rats were treated as in Figure 2. Blood samples were collected for the
measurement of ionized Ca, serum Ca, Pi, and PTH levels. Mean ± standard error was calculated for each group. Unpaired t-test with 95%
conﬁdence intervals of diﬀerence was performed for statistical comparisons. ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001 versus Day 0 (before dosing
at six weeks after the surgery). #P<. 05 versus Sham. ++P<. 01 versus paricalcitol at the same dose.
Table 1: Physiological parameters in Sham rats or 5/6 nephrectomized rats fed a hyperphosphatemia-inducing diet.
Parameters Sham 5/6 NX-vehicle 5/6 NX-paricalcitol 5/6 NX-doxercalciferol
— — 0.33μg/kg 0.33μg/kg
Creatinine (mg/dL) 0.45 ± 0.03 1.28 ± 0.13∗∗∗ 1.57 ± 0.33∗∗ 1.29 ± 0.11∗∗∗
BUN (mg/dL) 12.3 ± 0.3 59.1 ± 5.3∗∗∗ 60.1 ± 9.0∗∗∗ 60.5 ± 5.0∗∗∗
Ionized Ca (mmil/L) 1.35 ± 0.02 1.13 ± 0.04∗∗ 1.26 ± 0.06# 1.35 ± 0.03###
Total serum Ca (mg/dL) 9.95 ± 0.13 8.99 ± 0.35∗∗ 10.1 ± 0.27# 10.93 ± 0.23∗∗###
Total serum Pi (mg/dL) 6.50 ± 0.25 10.09 ± 0.76∗∗ 12.05 ± 1.89∗ 11.31 ± 1.05∗∗
CaxPi ((mg/dL)2) 64.8 ± 3.3 89.1 ± 4.0∗ 120.3 ± 18.2∗ 122.9 ± 10.6∗∗∗###
Serum PTH 142 ± 31 2504 ± 579∗∗ 1031 ± 382∗ 445 ± 135##
Mean ± SEM; ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001 versus Sham; #P<. 05, ##P<. 01, ###P<. 001 versus NX-vehicle; n = 8–11 per group.International Journal of Endocrinology 5
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Figure 4: Eﬀects of paricalcitol and doxercalciferol on serum PTH and PTH mRNA levels in uremic rats. The 5/6 NX rats on a
hyperphosphatemia-inducing diet were treated with vehicle, paricalcitol, or doxercalciferol at 0.33μg/kg, i.p., 3 times/week, for two weeks
(n = 8–11 per group). Blood samples and parathyroid gland were collected for the measurement of serum PTH (a) and PTH mRNA (b).
For (b), real-time RT-PCR was performed as described in Materials and Methods. The mRNA expression level was ﬁrst normalized to
the GAPDH mRNA level and then calculated as % of control (Sham-vehicle, 100%). One way ANOVA Dunnett test with 95% conﬁdence
intervals of diﬀerence was performed for statistical comparisons. ∗P<. 05, ∗∗P<. 01 versusSham. #P<. 05, ##P<. 01versus 5/6NX-Vehicle.
signiﬁcantly changed in the 5/6 NX-vehicle group (versus
Sham). Paricalcitol and doxercalciferol induced an increase
in serum and ionized Ca in a dose-dependent manner; the
eﬀect of doxercalciferol was much more profound than that
of paricalcitol. Although there was variation in the serum
phosphate (Pi) values (Figure 3(c)), both drugs at the tested
doses did not have a signiﬁcant eﬀect. These results are
consistent with a previous report by Slatopolsky et al. [7]
that paricalcitol is less hypercalcemic than doxercalciferol.
Figure 3(d) shows that serum PTH was elevated in the 5/6
NX rat, and was signiﬁcantly reduced by either paricalcitol
or doxercalciferol at the tested doses.
We then determined the eﬀects of these two drugs on
PTHmRNAexpressioninthe5/6NXrats.Inordertoinduce
parathyroid gland hypertrophy so that enough tissues could
be collected for real-time PCR analysis, the 5/6 NX rats were
put on a hyperphosphatemia-inducing diet containing 0.9%
phosphorous and 0.6% calcium [8] for 4 weeks, followed
by treatment with vehicle or drugs for two weeks. Table 1
summarizes the physiological parameters. Similar to the
study in Figures 2 and 3, the serum creatinine and BUN
levels were signiﬁcantly elevated in the 5/6 NX rats (versus
Sham). Paricalcitol at or doxercalciferol at 0.33μg/kg had no
signiﬁcant eﬀect on creatinine or BUN. The serum Ca or
iCa level was lower in the NX-vehicle group, while serum Pi
was signiﬁcantly higher. Both drugs at the tested dose raised
serumCaandiCa,butdidnotsigniﬁcantlychangetheserum
phosphate level (versus NX-vehicle). The CaxPi product was
increased by the drug treatment, although the value in the
paricalcitol group failed to reach a statistical signiﬁcance
(versus NX-vehicle). Figure 4 shows that the combination of
5/6 nephrectomy and the hyperphosphatemia-inducing diet
caused a 17-fold increase in the serum PTH level and a 4.6-
fold increase in PTH mRNA (versus Sham). Both paricalcitol
and doxercalciferol at the tested dose reduced serum PTH
and PTH mRNA.
To further investigate the eﬀects of paricalcitol and
doxercalciferol on PTH mRNA expression, we treated pri-
mary culture of pig parathyroid cells with diﬀerent con-
centrations of paricalcitol or the major active metabolite
of doxercalciferol (1α, 25-(OH)2D2, active doxercalciferol).
Figure 5(a)showstheresultsfromreal-timeRT-PCRanalysis
that paricalcitol decreased PTH mRNA eﬀectively in a
dose-dependent manner achieving a 75% inhibition at
100nM. Active doxercalciferol also suppressed PTH mRNA
in a similar manner. Figure 5(b) shows that paricalcitol or
active doxercalciferol did not have a signiﬁcant eﬀect on
VDR mRNA expression. Figure 5(c) shows that paricalcitol
induced the expression of CaSR mRNA in a dose-dependent
manner, while active doxercalciferol had no eﬀect.
Figure 6 compares the eﬀects of paricalcitol and active
doxercalciferol on the proliferation of the pig parathyroid
cells. During the 72 hours incubation period, the number of
parathyroid cells increased by ∼3-fold (versus Day 0). Both
drugs inhibited the proliferation of these cells.
We then treated the parathyroid cells with 1nM parical-
citol or active doxercalciferol for 30 minutes or 48 hours,
and then ﬁxed and stained cells with an anti-VDR antibody
to examine the eﬀect of these two drugs on the subcellular
localization of VDR. The nuclei were stained by propidium
iodide (red color). Figure 7 shows representative ﬁelds from
confocal microscopy. The pig parathyroid cells contained
a thin layer of cytoplasm over a large nucleus. In the
absence of VDRAs, VDR staining (green color) seemed more
dispersed in the cytoplasm in ∼90% of cells; approximately
10% of cells exhibited strong VDR staining in the nuclei6 International Journal of Endocrinology
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Figure 5: Eﬀect of paricalcitol and active doxercalciferol on the
expression of PTH, VDR, and CaSR mRNA in pig parathyroid
cells. Cells were treated with paricalcitol and active doxercalciferol
at indicated concentrations (in log M) for 24 hours. Samples were
processedandreal-timeRT-PCRperformed.ThemRNAexpression
level was normalized to the GAPDH mRNA level. C: control (no
drug treatment); doxer: doxercalciferol. Values shown are mean ±
the standard deviation (n = 4). One way ANOVA Dunnett test with
95% conﬁdence intervals of diﬀerence was performed for statistical
comparisons. ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001 versus Control (C,
no drug treatment). #P<. 05 versus Control (C).
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Figure 6: Eﬀect of paricalcitol and active doxercalciferol on the
proliferation of pig parathyroid cells. Cells were treated with
or without increasing concentrations of paricalcitol or active
doxercalciferol (doxer) for 72 hours. Data were expressed as % of
control (cells on Day 0, 100%). Each value shown is mean ± the
standard deviation (n = 4–8). One way ANOVA Dunnett test with
95% conﬁdence intervals of diﬀerence was performed for statistical
comparisons. ∗P<. 05, ∗∗P<. 01 versus Control (C, no drug
treatment).
(Figure 7(a)). Figures 7(b) and 7(c) show that, upon
treatment with 1nM paricalcitol or active doxercalciferol
for 30 minutes, an increase in VDR localization in the
nucleus was observed in >80% of cells; the eﬀects of both
drugs were similar. Interestingly, in cells treated with 1nM
paricalcitol continuously for 48 hours, VDR localization
was still observed in the nucleus in >60% of the cells. As
a comparison, >80% of the cells treated with 1nM active
doxercalciferol for 48 hours exhibited no VDR staining, and
the remaining VDR-positive cells exhibited a bright ring of
green color (VDR staining) surrounding the nucleus.
4. Discussion
VDRAs regulate PTH at the transcriptional level. However,
the serum PTH level is maintained by other mechanisms
including serum Ca and phosphate, which modulates the
parathyroid gland to secrete PTH from its storage granules.
It is known that diﬀerent VDRAs such as calcitriol, doxer-
calciferol, and paricalcitol exhibit diﬀerent eﬀects on raising
serum Ca. Calcitriol is about 10-fold more hypercalcemic
than paricalcitol, while doxercalciferol is ∼2-3-fold more
hypercalcemic [2, 9–11]. To investigate whether the diﬀerent
hypercalcemic eﬀect of VDRAs plays a role in serum
PTH suppression, we studied paricalcitol and doxercalciferol
becausethesetwodrugsaresimilarinpotencyinsuppressing
serum PTH with diﬀerent hypercalcemic eﬀects. Our data
from the 5/6 NX rats are consistent with the previous studies
[9–11] that paricalcitol and doxercalciferol are equally
eﬃcacious in suppressing serum PTH, but paricalcitol is less
hypercalcemic than doxercalciferol.International Journal of Endocrinology 7
Control, no drug
3×
(a)
Paricalcitol, 1nM
30 min 48 hr
(b)
Active doxer, 1nM
30 min 48 hr
(c)
Figure 7:LocalizationofVDRinpigparathyroidcells.Cellswereincubatedwithout(a)orwith1nMparicalcitol(b)oractivedoxercalciferol
(c) for 30 minutes or 48 hours, and then stained for VDR (green) and nucleus (red). The VDR staining alone was also shown in black and
white. (a): 3× magniﬁcation; (b) and (c): 2× magniﬁcation; doxer: doxercalciferol.
Since it is not practical to isolate parathyroid cells from
the rat due to the limited availability of the tissue, we
prepared primary culture of pig parathyroid cells. Previously
it has been shown that, in dispersed bovine parathyroid cells,
calcitriol reduced the expression of PTH [12]. Our results
using the pig parathyroid cells are consistent that VDRAs
suppress PTH mRNA expression and inhibit parathyroid cell
proliferation. Paricalcitol and active doxercalciferol have no
signiﬁcanteﬀectsonmodulatingtheVDRmRNAlevelinthe
parathyroid cells, although paricalcitol seems more eﬀective
in inducing the expression of CaSR mRNA. Paricalcitol may
“prime” the parathyroid cells to become more sensitive to
s e r u mC as i n c ep a r i c a l c i t o li sl e s se ﬀective in raising serum
Ca levels.
We demonstrate by confocal microscopy that VDRA
treatment of the pig parathyroid cells increases VDR staining
in the nucleus, which can be seen as early as 30 minutes
after the addition of paricalcitol or active doxercalciferol.
The observation, consistent with our previous studies in
the HL-60 promyelocytic leukemia cells, demonstrates that
VDR resides predominantly in the cytoplasm of the pig
parathyroid cells in the absence of VDRAs, and VDRA
treatment induces VDR to translocate into the nucleus [13].
Our observations seem to suggest that diﬀerent VDRAs may
have diﬀerential eﬀects on the subcellular distribution of
VDR after a prolonged incubation period. It is well known
that binding of agonists to the receptor stabilizes the VDR
via protecting the receptor from proteolytic degradation.
Therefore, it is possible that the diﬀerent eﬀects of these two
compounds on nuclear VDR staining could be an indication
of a diﬀerential intraparathyroid catabolism of the ligand-
bound VDR.
From this study, we demonstrated that the eﬀect of
VDRAs on suppressing serum PTH involves multiple factors
such as regulation of PTH and CaSR mRNA expression,
inhibition of parathyroid cell proliferation, and modulation
of serum Ca. These observations reﬂect the complexity of
the vitamin D axis in regulating the mineral homeostasis
system.
Abbreviations
VDR: Vitamin D receptor
PTH: Parathyroid hormone
NX: 5/6 nephrectomized
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